Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROHIT LOOMBA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1578593521
CMS profile
920380
Location
LA JOLLA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$59,929.28

51 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROHIT LOOMBA

NPI 1578593521 · CMS profile ID 920380

Allopathic & Osteopathic Physicians / Internal Medicine

LA JOLLA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578593521?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROHIT LOOMBA, NPI 1578593521, CMS profile ID 920380. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578593521?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ROHIT LOOMBA, NPI 1578593521, CMS profile ID 920380. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578593521?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ROHIT LOOMBA, NPI 1578593521, CMS profile ID 920380, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1578593521?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

51 matching records · $59,929.28 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 51 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–51 of 51.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Kowa Research Institute, Inc. $2,100.0001/18/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1075874083 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $201,115.82 112
PY2020 $135,173.13 38
PY2021 $106,247.50 28
PY2022 $64,286.79 29
PY2023 $153,169.07 42
PY2024 $59,929.28 51
PY2025 $245,285.32 117

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $133,865.00 1
PY2025 Principal investigator $349,886.65 121
PY2024 Principal investigator $346,213.92 74
PY2023 Principal investigator $6,388,539.71 23
PY2022 Recipient $412.01 3
PY2022 Principal investigator $931,768.05 80
PY2021 Recipient $3,873.00 2
PY2021 Principal investigator $911,669.69 75
PY2020 Recipient $145.50 1
PY2020 Principal investigator $4,095,425.70 75
PY2019 Recipient $705.39 1
PY2019 Principal investigator $1,116,412.10 89

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

122 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Madrigal Pharmaceuticals $6,558.08 11/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248253121
Principal investigator 1 Madrigal Pharmaceuticals $1,560.00 11/18/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252703
Principal investigator 1 Madrigal Pharmaceuticals $585.00 11/17/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248252670
Principal investigator 1 BioMarin Pharmaceutical Inc. $1,713.04 11/14/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580229
Principal investigator 1 BioMarin Pharmaceutical Inc. $4,315.85 11/14/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580231
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $455.00 11/14/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270546
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $962.00 11/07/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270528
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $97.50 11/05/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270524
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 10/29/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270518
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $97.50 10/29/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270520
Principal investigator 1 BioMarin Pharmaceutical Inc. $332.50 10/22/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580227
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $332.50 10/22/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223270510
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 10/17/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270508
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $682.50 10/03/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270502
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,108.00 10/01/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270480
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $227.50 10/01/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270482
Principal investigator 1 BioMarin Pharmaceutical Inc. $332.50 09/24/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580215
Principal investigator 1 BioMarin Pharmaceutical Inc. $332.50 09/24/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580217
Principal investigator 1 BioMarin Pharmaceutical Inc. $2,194.50 09/24/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580219
Principal investigator 1 BioMarin Pharmaceutical Inc. $3,426.08 09/24/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580221
Principal investigator 1 BioMarin Pharmaceutical Inc. $399.00 09/24/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580223
Principal investigator 1 BioMarin Pharmaceutical Inc. $259.35 09/24/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580225
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 09/19/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270454
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 09/19/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270456
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 09/19/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270458
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 09/19/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270460
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,558.50 09/05/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele No dispute reported 06/30/2026 1185538865
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 08/27/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270374
Principal investigator 1 Madrigal Pharmaceuticals $8,970.00 08/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249209
Principal investigator 1 Madrigal Pharmaceuticals $1,150.50 08/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249212
Principal investigator 1 Madrigal Pharmaceuticals $1,150.50 08/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249217
Principal investigator 1 Madrigal Pharmaceuticals $8,970.00 08/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249221
Principal investigator 1 Madrigal Pharmaceuticals $8,970.00 08/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249226
Principal investigator 1 Madrigal Pharmaceuticals $1,150.50 08/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249229
Principal investigator 1 Madrigal Pharmaceuticals $1,800.00 08/26/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248249234
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $455.00 08/22/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270370
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,300.00 08/06/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270342
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $455.00 08/06/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270344
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 08/06/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270346
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $195.00 08/06/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270348
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,503.16 08/06/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270350
Recipient BioMarin Pharmaceutical Inc. $133,865.00 07/25/2025 Covered Recipient Physician BMN-349 No dispute reported 06/30/2026 1248577924
Principal investigator 1 BioMarin Pharmaceutical Inc. $6,783.00 07/23/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580197
Principal investigator 1 BioMarin Pharmaceutical Inc. $4,592.49 07/18/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580191
Principal investigator 1 BioMarin Pharmaceutical Inc. $332.50 07/18/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580193
Principal investigator 1 BioMarin Pharmaceutical Inc. $6,783.00 07/18/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580195
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 07/18/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270326
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,189.50 07/02/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270308
Principal investigator 1 Madrigal Pharmaceuticals $390.00 06/19/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245854
Principal investigator 1 BioMarin Pharmaceutical Inc. $9,123.14 06/16/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580213
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,787.50 06/13/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270248
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,593.60 06/13/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270250
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $97.50 06/13/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270252
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $455.00 06/13/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270254
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $650.00 06/13/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270256
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,300.00 06/13/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270258
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,262.00 06/13/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270260
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $988.00 06/13/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270262
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,120.00 06/13/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270264
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 06/13/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270266
Principal investigator 1 Madrigal Pharmaceuticals $4,329.23 06/12/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245418
Principal investigator 1 Madrigal Pharmaceuticals $1,350.00 06/12/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245422
Principal investigator 1 Madrigal Pharmaceuticals $1,300.00 06/12/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245425
Principal investigator 1 Madrigal Pharmaceuticals $1,625.00 06/12/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248245429
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 06/06/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270242
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,341.00 05/28/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270220
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 05/28/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270222
Principal investigator 1 GlaxoSmithKline, LLC. $191.91 05/27/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192159420
Principal investigator 1 BioMarin Pharmaceutical Inc. $20,196.72 05/16/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580183
Principal investigator 1 BioMarin Pharmaceutical Inc. $8,805.93 05/16/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580185
Principal investigator 1 BioMarin Pharmaceutical Inc. $332.50 05/16/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580187
Principal investigator 1 BioMarin Pharmaceutical Inc. $5,918.50 05/16/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580189
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 05/07/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270192
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,817.20 05/07/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270194
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $195.00 05/07/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270196
Principal investigator 1 Madrigal Pharmaceuticals $600.00 05/06/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248243213
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,324.50 05/02/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
A Two Part Phase IIa b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants with Cirrhosis with Features of Portal Hypertension No dispute reported 06/30/2026 1185538863
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,077.95 05/01/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270190
Principal investigator 1 Madrigal Pharmaceuticals $1,647.83 04/28/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242798
Principal investigator 1 Madrigal Pharmaceuticals $3,451.50 04/23/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248242576
Principal investigator 1 BioMarin Pharmaceutical Inc. $1,667.82 04/16/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580211
Principal investigator 1 GlaxoSmithKline, LLC. $910.00 04/02/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192159416
Principal investigator 1 GlaxoSmithKline, LLC. $1,820.00 04/02/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192159429
Principal investigator 1 GlaxoSmithKline, LLC. $910.00 04/02/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192160936
Principal investigator 1 GlaxoSmithKline, LLC. $910.00 04/02/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192160950
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $455.00 04/02/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270142
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 04/01/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270130
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $104.00 04/01/2025 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270140
Principal investigator 1 GlaxoSmithKline, LLC. $1,170.00 03/28/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192159411
Principal investigator 1 GlaxoSmithKline, LLC. $1,950.00 03/28/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192159424
Principal investigator 1 GlaxoSmithKline, LLC. $3,900.00 03/28/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192160940
Principal investigator 1 GlaxoSmithKline, LLC. $754.00 03/28/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192160945
Principal investigator 1 GlaxoSmithKline, LLC. $988.00 03/28/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192160954
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,886.00 03/26/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270748
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 03/26/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270750
Principal investigator 1 BioMarin Pharmaceutical Inc. $8,631.70 03/14/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580209
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $227.50 03/14/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270734
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $650.00 03/14/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270736
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,262.00 03/14/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270738
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,170.00 03/14/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270740
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,365.00 03/14/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270742
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,799.62 03/12/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270732
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 03/03/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270730
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 02/21/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270726
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,543.30 02/21/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270728
Principal investigator 1 Intercept Pharmaceuticals, Inc. $16,465.40 02/20/2025 Non-covered Recipient Entity
The Regents of the University of California
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis No dispute reported 06/30/2026 1248171434
Principal investigator 1 BioMarin Pharmaceutical Inc. $42,791.42 02/19/2025 Non-covered Recipient Entity
The Regents of the University of California
BMN 349-102 No dispute reported 06/30/2026 1248580207
Principal investigator 1 Madrigal Pharmaceuticals $3,295.66 02/17/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248239851
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,412.12 02/12/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270724
Principal investigator 1 Madrigal Pharmaceuticals $4,329.23 01/24/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248238791
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 01/24/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270712
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $650.00 01/22/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270708
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $390.00 01/22/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
HEPATIC IMPAIRMENT No dispute reported 06/30/2026 1223270710
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $325.00 01/15/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270706
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,350.70 01/10/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270698
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $97.50 01/10/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270700
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,985.50 01/10/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270702
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $97.50 01/10/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270704
Principal investigator 1 Madrigal Pharmaceuticals $2,381.08 01/03/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248237927
Principal investigator 1 Madrigal Pharmaceuticals $1,190.54 01/03/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248237931
Principal investigator 1 Madrigal Pharmaceuticals $3,000.00 01/03/2025 Non-covered Recipient Entity
UNIVERSITY OF CALIFORNIA SAN DIEGO
A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION No dispute reported 06/30/2026 1248237935
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $650.00 01/03/2025 Covered Recipient Teaching Hospital
UCSD MEDICAL CENTER
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223270696